Investors Lend Satori $15 Million, Hoping It Converts To An Alzheimer's Treatment
This article was originally published in The Pink Sheet Daily
Executive Summary
The venture-backed Cambridge, Mass. firm says it can get its small-molecule gamma-secretase modulator into the clinic next year.
You may also be interested in...
Beyond A-Beta: New Approaches To Alzheimer’s
The Alzheimer’s Association International Conference is under way in Vancouver through July 19, but some of the most anticipated news regarding drug development for the disease is likely to take place later this year. There’s plenty of hope, but not much optimism that pivotal trials for bapneuzumab and solanezumab will succeed. Regardless of the outcome, the results will have an impact on which approaches to Alzheimer’s come next—and how they get funded.
Beyond A-Beta: New Approaches To Alzheimer’s
The track record for anti-amyloid beta Alzheimer’s treatments has been dismal. If upcoming results from pivotal trials for bapineuzumab and solanezumab are disappointing, they won’t scuttle the approach completely, but much more attention would shift toward other targets. We highlight two targets that have gained more attention of late, extracellular tau and ApoE4, and a diverse group of scientists working to move their work forward.
Lilly To Cease Development Of Alzheimer's Drug
Eli Lilly announced August 17 it would halt development of its Phase III Alzheimer's drug candidate semagacestat, casting some doubt on the efficacy of novel gamma secretase inhibitor drugs and slowing Lilly's late-stage pipeline as the company struggles to replace future revenues that will be lost to drugs going off patent.